secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2026-05-13T11:31:16+00:00
Accession:  0001171843-26-003346
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Q1 net income $169.7M ($0.88/share) on $179.1M revenue from Moderna settlement
--------------------------------------------------------------------------------

- Revenue $179.1M up from $1.8M YoY; $178.7M license revenue from Genevant related to Moderna settlement.
- Net income $169.7M vs net loss $24.5M in Q1 2025; diluted EPS $0.87.
- Moderna settlement: $950M noncontingent payment due July 2026; Arbutus expects ~$178.7M.
- Cash, equivalents and marketable securities $95.2M as of March 31, 2026.
- FDA granted Fast Track designation for imdusiran for chronic hepatitis B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/0001171843-26-003346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/f8k_051226.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-003346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer